The growing field of liquid biopsy and its Snowball effect on reshaping cancer management
The Journal of Liquid Biopsy,
Journal Year:
2025,
Volume and Issue:
unknown, P. 100293 - 100293
Published: March 1, 2025
Liquid
biopsy
(LB)
has
emerged
as
a
transformative
tool
in
oncology,
providing
minimally
invasive
approach
for
tumor
detection,
molecular
characterization,
and
real-time
treatment
monitoring.
By
analyzing
circulating
DNA
(ctDNA),
cells
(CTCs),
extracellular
vesicles
(EVs),
microRNA
(miRNA),
LB
enables
comprehensive
profiling
without
the
need
traditional
tissue
biopsies.
Over
past
decade,
research
this
field
expanded
exponentially,
leading
to
integration
of
into
clinical
practice
specific
cancer
types,
including
lung
breast
cancer.
In
2024,
Journal
Biopsy
(JLB)
published
innovative
studies
exploring
latest
advancements
technologies,
biomarkers,
their
applications
minimal
residual
disease
(MRD)
monitoring,
therapy
response
assessment.
This
review
synthesizes
recent
findings
on
role
monitoring
across
different
with
particular
focus
newly
context
within
translational
research.
Additionally,
it
highlights
emerging
techniques
such
fragmentomics,
artificial
intelligence,
multiomics,
paving
way
more
precise,
personalized
decisions.
Despite
these
advancements,
challenges
remain
standardizing
methodologies,
optimizing
validation,
integrating
routine
oncological
workflows.
mini-review
evolving
landscape
its
potential
revolutionize
diagnosis,
therapeutic
decision-making,
ushering
new
era
precision
oncology.
Language: Английский
Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors
Critical Reviews in Oncology/Hematology,
Journal Year:
2024,
Volume and Issue:
203, P. 104483 - 104483
Published: Aug. 17, 2024
Language: Английский
Pancreatic incidentaloma: incidental findings from history towards the era of liquid biopsy
eGastroenterology,
Journal Year:
2024,
Volume and Issue:
2(3), P. e100082 - e100082
Published: Sept. 1, 2024
This
report
provides
an
overview
of
the
most
common
diagnostic
methods
that
bring
to
light
incidental
findings
pancreatic
cancer.
It
reviews
impact
medical
imaging
and
genetic
assessment
on
definitions
incidentaloma
pancreas.
For
different
approaches
(eg,
MRI
CT)
for
affections
(cysts/intraductal
papillary
mucinous
neoplasia,
solid
lesions),
specific
guidelines
have
been
proposed
some
are
established.
Based
this,
we
summarise
differences
between
traditional
with
those
applied
in
PANCAID
project.
Biomarkers,
predispositions,
mutations
circulating
tumour
cells
give
rise
levels
concern.
The
final
part
discusses
risks
opportunities
associated
further
procedures
surgical
interventions.
From
ethical
perspective,
urging
question
is,
can
a
screening
based
liquid
biopsy
blood
samples
open
gateway
prevention
cancer-even
if
morbidity
lethality
today's
interventions
is
still
very
high?
Language: Английский